SHUTTLE PHARMACTCLS HLDGS INC Stock Price, News & Analysis

Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) has appointed Christopher Cooper as interim Co-Chief Executive Officer to enhance the company's capital markets and business capabilities. Dr. Anatoly Dritschilo will continue as Chairman of the Board and Co-CEO, focusing on scientific and clinical trial activities.

Cooper brings over 27 years of management and finance experience across various industries. He currently serves as President, CEO, and Founder of First Towers & Fiber Corp since 2017. Previously, he was President and CEO of Aroway Energy (2010-2017) and worked as a Corporate Consultant (1998-2010), raising over $100 million in debt and equity for clients.

The new Co-CEO structure aims to enable parallel execution of R&D, regulatory, and general business operations, with a focus on advancing the company's Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment and the development of their Diagnostics subsidiary.

Shuttle Pharmaceuticals (NASDAQ: SHPH) has provided a corporate update for 2024, highlighting significant progress in its cancer treatment programs. The company reported 40% enrollment completion in the Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment, with 16 out of 40 initial patients enrolled and 8 patients completing all seven cycles.

The trial is being conducted at several prestigious cancer centers including Georgetown University Medical Center and UNC Medical Center. Additionally, Shuttle Pharma's Diagnostics subsidiary entered a research agreement with UCSF to develop a PSMA ligand for cancer diagnosis and therapy.

The company secured additional funding, including a $237,500 investment from CEO Dr. Anatoly Dritschilo. The company's focus remains on developing radiation sensitizers to enhance cancer treatment outcomes and advancing diagnostic tools for predicting radiation therapy success, particularly in prostate cancer treatment.

Shuttle Pharmaceuticals Holdings (SHPH) has reached 25% enrollment in the initial randomized portion of its Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma treatment. The trial design involves randomizing 40 patients into two dose levels: 1,200 mg/day and 960 mg/day, followed by enrolling 14 additional patients at the optimal dose.

The trial focuses on patients with IDH wild-type, methylation negative glioblastoma, where currently less than half survive beyond 12 months after diagnosis. The study is being conducted at six nationally recognized cancer centers. Ropidoxuridine, Shuttle Pharma's lead radiation sensitizer candidate, has received FDA Orphan Drug Designation.

The company aims to serve an estimated 400,000 US patients treated with radiation therapy for curative purposes annually, with this market expected to grow by 22% over the next five years.

Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) has announced its participation in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025. CEO Anatoly Dritschilo, M.D., will lead a webcasted fireside chat at 3:30 p.m. Eastern time.

During the virtual event, Dr. Dritschilo will outline the company's 2025 plans, focusing on their Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma treatment. The trial is currently enrolling patients at six nationally recognized cancer centers, targeting IDH wild-type, methylation negative glioblastoma.

The discussion will also cover developments in the Shuttle Diagnostics subsidiary, particularly the PC-RAD test for predicting radiation therapy outcomes in prostate cancer patients, and their work on a PSMA ligand as a potential theranostic molecule.

Shuttle Pharmaceuticals Holdings (SHPH) has entered into a sponsored research agreement with the University of California, San Francisco (UCSF) to advance pre-clinical development of its PSMA-B ligand for prostate cancer diagnosis and treatment. The research will focus on developing the molecule as a potential diagnostic and therapeutic (theranostic) tool.

UCSF researchers, led by Dr. Robert Flavell, will develop radiosynthetic methods for producing [18F]FPA-ACUPA probe, investigate cellular binding properties, and explore diagnostic potential across various prostate cancer phenotypes. The global PSMA PET Imaging Market reached $1.5 billion in 2022 and is projected to reach $2.0 billion by 2030.

Shuttle Pharmaceuticals Holdings (SHPH) announced the enrollment and dosing of its first patient at UVA Cancer Center in its Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma treatment. The trial, conducted across six cancer centers, will initially include 40 patients randomized into two doses (20 @ 1,200 mg/day and 20 @ 960 mg/day), followed by an additional 14 patients at the optimal dose. The study targets IDH wild-type, methylation negative glioblastoma patients, who currently have treatment options with radiation therapy. The company previously received FDA Orphan Drug Designation for Ropidoxuridine.

Shuttle Pharmaceuticals Holdings (NASDAQ: SHPH) provided a Q3 2024 corporate update highlighting key developments. The company successfully dosed the first three patients in its Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment and finalized agreements with all six planned enrollment sites. Financial updates include paying off a $4.3M Senior Secured Convertible Note, completing a $4.5M public offering, and closing a $790,000 convertible note offering. The company reported a cash balance of $4.1M as of October 31, 2024.

The Phase 2 trial will enroll 40 patients initially, randomized into two dosage groups, with plans to add 14 more patients once the optimal dose is determined. The trial is expected to complete in 18-24 months.

Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) has announced pricing of a $4.5 million public offering priced at-the-market. The offering includes up to 2,950,820 shares of common stock (or pre-funded warrants) and warrants at $1.525 per share and accompanying warrant. The warrants, exercisable at $1.40 per share, will expire in five years. Net proceeds will fund IND-enabling and Phase I/II clinical trials, including $2.3 million payment to Theradex Systems for Phase II trials of Ropidoxuridine. The offering is expected to close around October 31, 2024.

Shuttle Pharmaceuticals (Nasdaq: SHPH) has fully paid off its Senior Secured Convertible Note issued in January 2023, which had an initial balance of $4.3 million. The company made $1.3 million in cash payments and issued 1,094,970 shares, bringing total outstanding shares to 2,946,099. In October 2024, the company secured $790,000 in gross proceeds through a convertible note and warrant offering, including $237,500 from CEO Dr. Anatoly Dritschilo.

The company is advancing its Phase 2 clinical trial for glioblastoma treatment, with five out of six trial sites ready to begin treating patients. The trial will initially include 40 patients randomized into two dose groups, with plans to add 14 more patients once the optimal dose is determined. The trial is expected to complete in 18-24 months.